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Abstract
The term “fibrosis” refers to a spectrum of connective tissue disorders characterized by the excessive accumulation of extracel-
lular matrix leading to organ dysfunction and, ultimately, failure. Fibrosis affects millions of patients worldwide and often
manifests itself as a late-stage pathological condition associated with poor prognostic outcome. Although the aetiology and
clinical course vary widely depending on the affected organ, fibrotic degeneration of different tissues is underpinned by similar
molecular and cellular mechanisms, most notably the persistence and dysregulated activity of myofibroblasts. A systematic
search of clinical trials was conducted using PubMed and Cochrane to qualitatively evaluate the effectiveness of different
therapeutic approaches to the pharmacological targeting of myofibroblasts in patients affected by fibrotic disorders. The system-
atic search and screening returned 54 eligible clinical trials, 38 of which reported an improvement of the patients’ symptoms
following treatment. The majority of the eligible articles focused on fibrotic degeneration of the respiratory system, skin, liver,
and kidneys. The evaluation of clinical data unearthed commonalities between strategies that successfully ameliorated symptoms
in patients affected by the same fibrotic disorder. However, none of the treatments evaluated in this study could improve
symptoms across a range of fibrotic pathologies. These results indicate that, although no “one size fits all” treatment for fibrosis
has yet been identified, the systematic analysis of clinical data can be used to inform the development of therapeutical strategies
tailored to suit the diverse aetiology of each fibrotic condition.
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Introduction
Background and Rationale of the Study
Despite extensive investments and research efforts, no such
thing as a “cure for fibrosis” has been as of yet discovered, and
replacement of the affected organ remains the most frequent
treatment strategy. There are several factors that render fibro-
sis treatment a challenging matter [1]. Aside from its inherent-
ly heterogeneous nature (i.e. it is not a distinct pathology, but
rather an umbrella term covering a wide spectrum of condi-
tions), fibrosis often represents a pathological end-state, and in
most cases, it is only diagnosed after tissue degeneration has
already taken place to a significant extent. Moreover, the in-
creased deposition of highly cross-linked extracellular matrix
(ECM) represents a significant physical barrier to the delivery
of therapeutical agents to the affected tissue. As mentioned in
the previous section, clinical intervention is further complicat-
ed by the self-sustaining nature of myofibroblasts that, by
secreting profibrotic cytokines and generating tensile force,
produce a local environment permissive to the persistence
and propagation of fibrosis [2].
Given their fundamental role in the onset and progression
of fibrosis, myofibroblasts are considered appealing pharma-
cological targets [3]. An increasing body of experimental ev-
idence (summarized in Table 1) seems to indicate that the
cytokines basic fibroblast growth factor (bFGF or FGF2),
transforming growth factor β3 (TGF-β3), interferon γ
(IFN-γ), and interleukin-1 (IL-1) are appealing candidates
for the pharmacological targeting of myofibroblasts [4].
While there indeed are several other compounds that have
been shown to regulate myofibroblast activity in a preclinical
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Table 1 Preclinical evidence on the antifibrotic effect of the cytokines bFGF, IFN-γ, TGF-β3, and IL-1
Ref Treatment Model Outcome
[27] FGF-2 (bFGF) Wistar rats ↑ Myofibroblast apoptosis
↓ α-SMA expression
[28] FGF-2 (bFGF) Porcine valvular interstitial cells ↓ α-SMA expression
↓ TGF-β1 signalling
↓ Contraction
[29] FGF-2 (bFGF) Porcine dermal cells ↓ α-SMA expression
↓ Cell spreading
[30] FGF-2 (bFGF) Wistar rats ↑ Myofibroblast apoptosis
↓ α-SMA expression
[31] FGF-2 (bFGF) Human adipose-derived mesenchymal stem cells ↓ Cell spreading
↓ α-SMA expression
[32] FGF-2 (bFGF) C57BL/ksJ db/db mice ↑ Myofibroblast apoptosis
↓ Scarring
[33] FGF-2 (bFGF) New Zealand rabbits ↓ Scarring
↓ α-SMA expression
[34] FGF-2 (bFGF) Human cardiac myofibroblasts ↓ Contraction
↓ TGF-β1 signalling
↓ ECM remodelling
↓ Cell spreading
[35] IFN-γ Human skin fibroblasts and wound healing myofibroblasts ↓ Contraction
↓ α-SMA expression
↓ Total collagen production
[36] IFN-γ Wistar rats ↓ Scarring
↓ α-SMA expression
↓ Collagen III and IV expression
[37] IFN-γ Rat hepatic stellate cells ↓ α-SMA expression
↓ Proliferation
↓ Collagen I and IV expression
↓ Fibronectin expression
[38] IFN-γ Rat hepatic stellate cells ↓ α-SMA expression
↓ Proliferation
[39] IFN-γ knockout C57BL/6 mice ↑ TGF-β1 expression
↑ α-SMA expression
[40] IFN-γ Wistar rats ↓ Myofibroblast density
↓ Collagen III expression
↓ Hydroxyproline content
[41] IFN-γ Human gingival fibroblasts and myofibroblasts ↓ α-SMA expression
↓ Collagen I expression
↓ Cell spreading
[42] IFN-γ WI-38 human fibroblasts ↓ α-SMA expression
[43] IFN-γ Rat palatal fibroblasts ↓ α-SMA expression
↓ Proα2(I) collagen expression
↓ Contraction
[44] IFN-γ Human foetal lung fibroblasts ↓ α-SMA expression
↓ Cell spreading
↓ Hydroxyproline content
[45, 46] IFN-γ (free and PEGylated) C57BL/6 mice; NIH3T3 mouse fibroblasts ↓ α-SMA expression
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setting, the evidence surrounding their effectiveness is sparse,
and they have therefore been excluded from this review for the
sake of conciseness.
While there is no shortage of in vitro and animal studies
aimed at specifically triggering myofibroblasts apoptosis and/
or their reversal to a non-contractile phenotype, the clinical
translatability of the findings remains mostly elusive [5]. At
the time this reviewwas written, a preliminary PubMed search
for systematic reviews and meta-analysis using the MeSH
term “Myofibroblasts” returned only 12 articles, 8 of which
discussed the role of myofibroblasts in cancer. The remaining
4 articles were on the topic of fibrosis; however, 2 of them
were focused on the identification of diagnostic markers,
while the other 2 evaluated preclinical evidence, respectively,
from studies on mice and rats.
The aim of the present paper is to research and systemati-
cally review published human clinical trials to evaluate current
evidence on the pharmacological treatment of fibrosis, with
specific regards to therapeutical strategies aimed at targeting
the activity and persistence of myofibroblasts.
Outline of Myofibroblast Biology and Ontology
Myofibroblasts were first identified in the granulation tissue of
healing skin wounds and described as a transient population of
“modified fibroblasts” showing ultrastructural features typi-
cally associated with smooth muscle (SM) cells [6]. While
the phenomenon of wound contraction was already known
to researchers in the early twentieth century [7], the underlying
cellular events remained elusive until the discovery that
Table 1 (continued)
Ref Treatment Model Outcome
↓ Fibronectin expression
↓ Collagen I and III expression
[47] IFN-γ C57BL10J+/+ mice; muscle-derived fibroblasts ↓ Total collagen production
↓ α-SMA expression
[48] TGF-β3 Wistar rats; human dermal fibroblasts; rat dermal fibroblasts ↑ Total collagen production (in vivo)
↑ α-SMA expression (in vitro)
[49] TGF-β3 Sprague-Dawley rats ↓ Scarring
↓ Fibronectin expression
↓ Collagen I and III expression
[50] TGF-β3 Human corneal fibroblasts (3D culture) ↓ Collagen III expression
↓ α-SMA expression
[51] TGF-β3 transduction CD1 mice; murine dermal fibroblasts ↓ α-SMA expression
↓ Scarring
[52] TGF-β3 CL/Fraser mice ↓ Scarring
↓ Collagen I expression
↓ α-SMA expression
[53] TGF-β3 C57BL/6 mice; human keloid fibroblasts ↓ α-SMA expression
↓ Collagen I expression
↓ Scarring
[54] IL-1α Human fibroblast/keratinocyte co-culture ↓ α-SMA expression
↑ NF-κB activation
↓ TGF-β1 signalling
[55] IL-1α/β (endogenous) New Zealand rabbits ↓ α-SMA expression
[56] IL-1α/β Rabbit corneal myofibroblasts ↑ Myofibroblast apoptosis
[57] IL-1β Human dermal and lung fibroblasts ↓ α-SMA expression
↓ GLI1 expression
↓ Collagen I expression
↓ LOX expression
↑ MMP1, MMP2, MMP9,
and MMP14 expressions
[58] IL-1β Rat lung fibroblast ↑ Myofibroblast apoptosis
↓ α-SMA expression
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myofibroblasts could generate mechanical tension within the
healing wound and contract the surrounding ECM, ultimately
pulling together the wound edges and facilitating their closure
[8, 9].
The distinctive biochemical, morphological, and functional
features of myofibroblasts have been widely described and are
summarized in Fig. 1. While myofibroblasts are akin to SM
cells in the fact that they express α-smooth muscle actin (α-
SMA) and are able to generate tractional forces, the former are
characterized by the lack of concomitant expression of other
SM-specific cell markers including SM myosin heavy chain,
desmin, h-caldesmon, and smoothelin [5]. Moreover, unlike
SM cells, myofibroblasts are typically characterized by the
incorporation of actin into bundles of microfilaments known
as stress fibres [10].
The overexpression of α-SMA is crucial towards the
maturation of focal adhesions (FA) into supermature fo-
cal adhesions (also referred to as fibronexi), character-
ized by a transmembrane association of contractile cyto-
skeletal elements and extracellular fibronectin (typically,
the myofibroblast-specific ED-A fibronectin splice vari-
ant) [11]. The specialized transmembrane association of
α-SMA-positive stress fibres and extracellular ED-A fi-
bronectin underpins the key functional feature of
myofibroblasts, which is to generate tensional force and
transmit it to the surrounding ECM [12].
ECM production and remodelling is a key hallmark of
myofibroblast activity: in addition to the de novo synthesis
and secretion of ED-A fibronectin, myofibroblasts are charac-
terized by the deposition of other ECM components such as
collagen (I, III, IV, V, VI) and proteoglycans, as well as by the
secretion of matrix-crosslinking enzymes including lysyl
oxidase (LOX) and lysyl hydroxylase 2 (LH2) [13, 14].
Fibrotic degeneration is also associated with an altered bal-
ance between matrix metalloproteinases (MMPs) and tissue
inhibitors of metalloproteinases (TIMPs). Interestingly, while
it would be reasonable to postulate that matrix-degrading en-
zymes exert an antifibrotic activity and their inhibitors a
profibrotic one, that does not appear to always be the case,
with the expression of different MMPs and TIMPs causing
differential effects depending on their type and localisation
[15].
The discovery of the fundamental role of myofibroblasts in
physiological and pathological wound healing has spurred
considerable research into their origin and differentiation
mechanisms [16]. Traditionally, myofibroblasts were thought
to exclusively arise from the activation of quiescent popula-
tions of local fibroblasts in response to a tissue injury. While
this is frequently the case (particularly with regard to skin
wounds), it is now clear that myofibroblasts can originate from
a wide array of both mesenchymal and non-mesenchymal pre-
cursor cells [17, 18]. Typical examples of mesenchymal pre-
cursors of myofibroblasts include fibrocytes, pericytes, SM
cells, as well as adipose and bone marrow-derived stromal/
stem cells [19, 20]. In addition, non-mesenchymal precursors
have been shown to transdifferentiate into myofibroblasts via
epithelial-mesenchymal transition (EMT) and endothelial-
mesenchymal transition (EndMT). Increasing evidence indi-
cates that EMT and EndMT might play a role in the develop-
ment and progression of renal and pulmonary fibrosis; howev-
er, the in vivo significance of these pathways is still a matter of
debate [21].
While myofibroblasts can originate from a wide range of
precursor cells, the differentiation process in different tissues
Fig. 1 Key hallmarks of the
myofibroblast phenotype and
main promoting/inhibiting factors
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(and from different sources) is underpinned by a shared set of
stimuli. It is widely accepted that the cytokine transforming
growth factor β1 (TGF-β1) plays a central role in the devel-
opment and maintenance of the myofibroblasts phenotype.
Indeed, TGF-β1 is not the sole biochemical factor responsible
for the differentiation process. Multiple intracellular and ex-
tracellular molecular cues (summarized in Fig. 1) have been
identified as myofibroblasts-inducing factors, including ECM
components, growth factors, miRNAs, and reactive oxygen
species (ROS) [22, 23].
Myofibroblasts have been described as a “paradigm for a
mechanically active cell”: both in vivo and in vitro, the me-
chanical properties of the cellular microenvironment direct the
differentiation process in concert with soluble cues [24]. The
formation ofα-SMA-negative stress fibres and mature FA can
be observed at Young’s moduli ranging from ∼ 3 to ∼ 15 kPa,
hallmarking the so-called proto-myofibroblast phenotype.
Further increases in substrate stiffness result in the incorpora-
tion of α-SMA in the stress fibres and in the supermaturation
of FA [12]. Profibrotic mechanical signals are transduced both
directly via the Rho cascade (due to the physical continuity of
cytoskeletal and ECM components at FA sites) and indirectly
via the release of latent TGF-β1 stores from the ECM [25, 26].
It is important to highlight that, by secreting TGF-β1 and
generating high levels of mechanical tension, myofibroblasts
produce both of the “master regulators” that promote their
own generation and survival; this positive feedback loop sus-
tains their dysregulated persistence and activity, contributing
to the well-documented difficulty of the clinical treatment of
fibrosis [2].
Methods
This study was designed in accordance with PRISMA guide-
lines to research existing literature and investigate the impact
of different pharmacological interventions (compared to
placebo-treated or untreated controls) on patients affected by
fibrotic disorders. The effectiveness of different therapeutical
strategies was qualitatively assessed on the base of changes in
fibrosis-associated biochemical, structural, and functional
markers. Figure 2 provides a schematic representation of the
search and selection process used in this review.
Fig. 2 Flow chart of the search
and inclusion strategy used for
this review, designed according to
PRISMA guidelines
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Search Strategy
Although their key role in the aetiology of fibrotic conditions
is widely acknowledged, myofibroblasts are not always ex-
plicitly mentioned in clinical trials, that often focus on describ-
ing the specific condition (e.g. Dupuytren’s disease), interven-
tion (e.g. IFN-γ administration), and measurable outcomes
(e.g. reduction of TGF-β1 levels) rather than the underlying
cellular events. To overcome this limitation, the cytokines that
had been preclinically identified as the most promising
myofibroblast-inhibiting agents have been included in the
search as proxies. Appropriate MeSH terms were used in all
searches to ensure the inclusion of articles containing syno-
nyms of the desired keywords. The search string (excluding
quotation marks) “myofibroblast* OR ((transforming growth
factor beta 3 OR interferon-gamma OR fibroblast growth fac-
tor 2 OR interleukin-1) AND fibrosis)”was used to search the
PubMed and Cochrane databases, and the results were filtered
by article type to only include human clinical trials.
Exclusion/Inclusion Criteria
The following exclusion criteria were applied while screening
titles and abstracts: (e1) duplicated references, (e2) articles not
in English, (e3) studies not on human patients, (e4) content
irrelevant to the aims of the study. The remaining articles were
evaluated for eligibility using the following inclusion criteria:
(i1) full text available, (i2) not a conference abstract book or
poster, (i3) human patients with fibrotic disease, (i4) pharma-
cological intervention carried out, (i5) outcome provided, (i6)
fibrosis/myofibroblast marker(s) assessed with reference to a
control group.
Results
After screening and evaluation of the search results, a total of 54
clinical trials (schematically described in Table 2) were deemed
eligible for qualitative discussion. The majority of the eligible
articles focused on fibrotic degeneration of the respiratory sys-
tem (16 articles), skin (14 articles), liver (10 articles), and kid-
ney (8). In the interest of clarity, the results are grouped and
presented on the base of the affected organ targeted in the clin-
ical trials. Due to the relative shortage of information, fibrotic
conditions discussed in 3 or less of the eligible articles are
pooled together in “Other Organs and Syndromes”.
Lungs and Airways
Idiopathic Pulmonary Fibrosis
Amongst the papers identified in this study, pharmacological
treatment of idiopathic pulmonary fibrosis (IPF) was the
subject of 8 clinical trials, 6 of which tested the effects of
IFN-γ administration on IPF patients. Despite the shortage
of conclusive data on their efficacy, systemic corticosteroids
are frequently prescribed to IPF patients. Ziesche and col-
leagues investigated the effects of supplementing a low-dose
prednisolone regime with IFN-γ on IPF patients who did not
respond to glucocorticoids [59]. While lung function declined
in all patients in the prednisolone-only group, significant in-
creases from the baseline were observed in arterial pO2 and
lung capacity in the prednisolone plus IFN-γ group. A suc-
cessive study analysed biomarkers’ levels in lung biopsies and
bronchoalveolar lavage fluid (BALF) of IPF patients treated
with IFN-γ, concluding that “IFN-γ downregulates molecules
associated with fibrosis, proliferation, and inflammation, and
upregulates molecules associated with antimicrobial defense
and antiangiogenesis” [60]. The effect of IFN-γ on alleviating
functional markers of fibrosis was further confirmed by the
observation that IFN-γ treatment caused an improvement in
total lung capacity (TLC), diffusing capacity of the lungs for
carbon monoxide (DLCO), and arterial pO2 in IPF patients
[61, 62]. However, two placebo-controlled randomized trials
involving respectively 330 and 826 IPF patients not only
failed show any improvement following IFN-γ treatment but
also reported significant adverse effects. In the first of the two
studies, IFN-γ-treated patients did not show any improvement
in lung function, gas exchange, and quality of life [63].
Moreover, an increase in cases of pneumonia and constitution-
al symptomswas observed in the treatment group compared to
the placebo group. Similarly, the INSPIRE trial was prema-
turely stopped due to the lack of improvement in IFN-γ-
treated patients compared to the control group, and the obser-
vation that nearly all treated patients experienced at least one
adverse effect, with several subjects showing increased con-
stitutional symptoms [64].
The tyrosine-kinase inhibitor nintedanib has been used as
an alternative to corticosteroids for the treatment of IPF. Two
replicate randomized phase III trials (INPULSIS-1 and
INPULSIS-2) were carried out to verify the effectiveness
and safety of nintedanib compared to placebo on 1066 IPF
patients [65]. Despite the onset of diarrhoea in < 5% of the
subjects, patients in the treatment group showed a reduction in
the decline of forced vital capacity (FVC), suggesting that
nintedanib administration might be a promising strategy for
IPF treatment. Conversely, a recent phase II randomized trial
indicated that neutralization of circulating interleukin-4 and
interleukin-14 via the bispecific immunoglobulin
SAR156597 did neither ameliorate lung functionality (FVC
and DLCO) nor reduced disease progression/mortality in IPF
patients [66].
Serum amyloid P (SAP, also known as pentraxin 2) phys-
iologically regulates differentiation of circulating monocytes
into fibrocytes and has shown antifibrotic potential in animal
experiments. Its pharmacokinetics, safety, and efficacy in
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Table 2 Summary of clinical studies identified via systematic search.
All abbreviations used in this table are described in the main body of the
text. *Current status is indicated as M if the drug is marketed in one or
more countries for the specific use described in the trial, MO if marketed
for other uses, NM if non-marketed
Ref Treatment Key outcomes Side effects Current
status*
[59] Subcutaneous IFN-γ in IPF patients ↑ pO2
↑ Lung capacity
Fever, chills, muscle pain for the first 9–12 weeks MO
[60] Subcutaneous IFN-γ 1b in IPF patients ↓ Fibrosis, proliferation, and inflammation
markers
↑ Antimicrobial and antiangiogenesis markers
Headache, pyrexia, fatigue MO
[61] Inhaled IFN-γ in IPF patients ↑ IFN-γ lung deposition
↑ IFN-γ in BAL
No therapeutic conclusions were drawn
Cough MO
[62] Subcutaneous IFN- γ or colchicine in IPF
patients
↓ TGF-β1 expression in colchicine group
↓ IL-18 in BAL for both groups
↑ DLCO in IFN-γ group
↑ pO2 in IFN-γ group
Not discussed MO
[63] Subcutaneous IFN-γ 1b in IPF patients No improvement in lung function, gas
exchange, and quality of life.
Headache, fever, rigours, myalgia, influenza-like
symptoms
MO
[64] Subcutaneous IFN-γ 1b in IPF patients No improvement in clinical symptoms and
survival
Cough, headache, fatigue, influenza-like symp-
toms
MO
[65] Oral nintedanib in IPF patients ↓ FVC decline rate Diarrhoea M
[66] Subcutaneous SAR156597 in IPF patients No improvement in FVC, DLCO, and
mortality.
Worsening of IPF, cough, diarrhoea, viral upper
respiratory tract infection, bronchitis
NM
[67] Intravenous recombinant SAP
(pentraxin-2) in PF patients
↓ Fibrocyte count in whole blood No differences compared to placebo NM
[68] Intravenous recombinant SAP
(pentraxin-2) in IPF patients
↓ FVC decline rate
↑ 6-min walking distance
Cough NM
[69] Inhaled beclomethasone dipropionate in
asthma patients
↓ Collagen III and TIMP1
↓ Myofibroblasts and inflammatory cells
↑ MMP-9
↑ FEV1 and DMin
Not discussed M
[70] Inhaled budesonide or combined
budesonide/formoterol in asthma pa-
tients
↓ Sputum eosinophilia in both groups
↓ Submucosal myofibroblasts in combined
treatment group
↓ Late asthmatic response in combined
treatment group
Not discussed M
[71] Oral montelukast in mild asthma patients ↓ Airway wall myofibroblasts
↓ Lymphomononuclear cells
↑ Neutrophils
Not discussed M
[72] Inhaled IFN-γ 1b in patients with cystic
fibrosis lung disease
No improvement in FEVand sputum bacterial
density
Dyspnea, hemoptysis, pulmonary congestion,
exacerbation of symptoms
MO
[73] Subcutaneous IFN-γ 1b and oral predniso-
lone in bronchiolitis patients
↑ FEV1
↓ Dyspnea and hospitalization
Not discussed MO
[74] Inhaled fluticasone propionate in clinically
stable lung transplant recipients
No improvement in FEVand BOS occurrence Not discussed MO
[75] Intradermal avotermin (human
recombinant TGF-β3) in skin wounds
(healthy volunteers)
Improved scar VAS score Transient erythema and oedema NM
[76] Intradermal avotermin in skin wounds
(healthy volunteers)
Improved scar VAS score Incidence comparable to placebo NM
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Table 2 (continued)
Ref Treatment Key outcomes Side effects Current
status*
[77] Intradermal avotermin in varicose leg veins
removal surgery patients
Improved scar VAS score Incidence comparable to placebo NM
[78] Intradermal avotermin in scar revision
surgery patients
Improved scar VAS score
↓ Scar surface area
Incidence comparable to placebo
Four serious adverse events possibly related to
treatment
NM
[79] Topical bFGF (FGF-2) in skin graft recipi-
ents
↑ Cytoplasmic area
↑ Collagen bundle organization
↓ Post-operative scar colour change
Not discussed MO
[80] Topical bFGF (FGF-2) in paediatric
second-degree burn patients
↑ Skin/scar colour match
↓ Hypertrophic scar formation
Improved scar pigmentation, pliability, height
and vascularity after one year
Not discussed MO
[81] Intralesional IFN-γ in keloid scar patients ↓ Keloid height
↓ Collagen bundles thickness
↓ Neutrophils in stratum corneum
Transient headache and myalgia, both resolved
within 4 h
MO
[82] Post-excision intralesional IFN-γ in keloid
scar patients
No improvement in keloid recurrence and size Incidence comparable to placebo MO
[83] Intralesional IFN-γ in patients with local-
ized scleroderma
↓ Number of new lesions
No improvement in lesion size and collagen I
production
Arthralgia, fatigue, and dizziness MO
[84] Topical pirfenidone in patients with
localized scleroderma
↓ mLoSSI score
↓ Skin hardness
↓ Dermal infiltration
↓ Reticular dermis fibrosis
Mild transient burning sensation at the site of
application
MO
[85] Oral nilotinib in patients with diffuse
cutaneous systemic sclerosis
Patients with a decrease in MRSS showed a
concomitant overexpression of TGFBR and
PDGFRB
Asymptomatic changes in liver function test
2 Patients required hospitalization due to SAE
MO
[86] Intravenous rituximab in systemic sclerosis
patients
↑ Dickkopf-1 expression
↓ Dermal TGF-β expression
↑ Resolution of skin fibrosis
Not discussed MO
[87] Intravenous fresolimumab in early, diffuse
systemic sclerosis
↓ TGF-β-regulated markers
↓ Myofibroblast infiltration
Improved MRSS score
Anaemia, GI and gingival bleeding NM
[88] Extracorporeal photochemotherapy in
patients with diffuse cutaneous systemic
sclerosis
↓ Circulating TGF-β levels
↓ Dermal thickness
Improved MRSS score
None observed N/A
[89] Intramuscular IFN-γ in Hepatitis B patients
with hepatic fibrosis
↓ Hepatic fibrosis score
↓ Inflammatory score
↓ Nuclear Smad2
↓ Hepatic stellate cells
Transient fever, headache, muscular, skeletal and
limb pain, nausea, and decreased
white blood cell and platelet counts
MO
[90] Subcutaneous IFN-γ in hepatitis C patients
with hepatic fibrosis
Aggregate data show no significant antifibrotic
effect, however a reduction in fibrosis was
observed in selected patients
Increased liver enzymes in one patient MO
[91] Intramuscular IFN (subtype not specified)
and/or oral perindopril in patients with
refractory chronic hepatitis C
↓ Serum fibrosis markers in perindopril and
combination group
↓ TGF-β levels in combination group
Not discussed MO
[92] Subcutaneous IFN-γ 1b in hepatitis C pa-
tients with advanced hepatic fibrosis or
cirrhosis
No improvement in viral load and Ishak
fibrosis score
Headache, fatigue, rigours, myalgia, arthralgia,
pyrexia, influenza-like illness, pain, and mus-
cle cramps
MO
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Table 2 (continued)
Ref Treatment Key outcomes Side effects Current
status*
[93] Oral telmisartan or losartan in hepatitis C
patients on a ribavirin/pegylated IFN-α
2a regime
↓ Serum AST, GGT, and TGF-β levels in
telmisartan group
Headache and drowsiness in both telmisartan and
losartan group
MO
[94] Oral salvianolic acid B in hepatitis B
patients with hepatic fibrosis on a IFN-γ
regime
↓ Serum fibrosis markers
Improvement in ultrasound imaging score
None observed MO
(TC-
M)
[95] Korean red ginseng in hepatitis C patients
with hepatic fibrosis on an antiviral
regime
↓ Serum hyaluronic acid and TGF-β levels None observed MO
(TC-
M)
[96] Oral pioglitazone or vitamin E in patients
with non-alcoholic steatohepatitis
↓ Serum alanine and aspartate
aminotransferase in both groups
↓ Hepatic steatosis and globular inflammation
in both groups
Improved histological features in vitamin E
group
Weight gain in pioglitazone group MO
[97] Oral pioglitazone or vitamin E in patients
with non-alcoholic steatohepatitis
↓ Shh signalling
↓ Myofibroblast accumulation
Not discussed MO
[98] Subcutaneous pegbelfermin in
non-alcoholic steatohepatitis patients
↓ Hepatic fat fraction
↓ Liver stiffness
↓ Serum PRO-C3
Diarrhoea, GI-related adverse events, one case of
worsened depression
NM
[99] Microemulsion cyclosporin or tacrolimus
in kidney transplant recipients
↑ Collagen III and TIMP-1 expression in cy-
closporin group
Not discussed M
[100] CNI withdrawal or maintenance in kidney
transplant recipients
↑ Collagen and α-SMA in CNI maintenance
group
↑ TGF-β signalling in CNI maintenance group
↓ Enhancement of chronicity index in CNI
withdrawal group
↓ Myofibroblasts in withdrawal group
Not discussed M
[101] CNI-containing or CNI-free immunosup-
pressive regime on kidney transplant re-
cipients
↓ Serum TGF-β levels in CNI-free group
↓ Tubular lesions in CNI-free group
Not discussed M
[102] CNI-containing or CNI-free immunosup-
pressive regime on kidney transplant re-
cipients
No significant differences in fibrosis
progression
Aphthous stomatitis, acne, rash and graft
rejection in the CNI-free group. Leukopenia
and gingival hypertrophy in CNI-treated
M
[103] Oral losartan in hypertensive kidney
transplant recipients
↓ Plasma TGF-β1 levels
↓ Histopathological progression rate
None observed M
[104] Oral spironolactone in patients with chronic
kidney disease
↓ Urinary TGF-β1 levels
↓ Proteinuria
None observed M
[105] Oral aliskiren or perindopril in patients with
non-diabetic kidney disease
↑ Plasma renin levels in both groups
↑ Urinary TGF-β1 levels in both groups
Not discussed MO
[106] Oral prednisolone in patients with adult
diffuse proliferative IgA nephropathy
↓ α-SMA expression
↓ Mesangial cell proliferation
↓ ECM accumulation
None observed MO
[107] Subconjunctival CAT-152 in glaucoma pa-
tients undergoing first-time
trabeculectomy
No improvements observed in intraocular
pressure, bleb vascularity, and
trabeculectomy failure rate
None observed NM
[108] Intravitreal bevacizumab in patients with
proliferative diabetic retinopathy
↑ Cell apoptosis
No improvement observed in α-SMA expres-
sion and collagen deposition
Not discussed MO
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treating pulmonary fibrosis were initially assessed in a small-
scale placebo-controlled randomized clinical trial involving
26 healthy volunteers and 3 patients with pulmonary fibrosis
[67]. The study indicated that recombinant SAP was well
tolerated and resulted in a significant (30–50%) reduction in
circulating fibrocytes in PF patients after 24 h from adminis-
tration. More recently, a larger randomized placebo-controlled
phase II trial corroborated the preliminary results: SAP-treated
IPF patients exhibited significant reduction in FVC decline
and improved scores in the 6-min walk test [68].
Asthma
Airway remodelling and fibrotic degeneration are frequently
associated with chronic inflammation in asthmatic patients, a
process in which myofibroblasts are known to play a crucial
role. Inhaled corticosteroids are effective in the management
of asthma, and have been shown to reduce inflammation and
airways remodelling. Asthmatic patients treated with
beclomethasone dipropionate exhibited a significant reduction
in collagen III deposition and a concomitant decrease of
MMP-9 and increase of TIMP-1 [69]. A significant reduction
in the numbers of myofibroblasts and inflammatory cells (eo-
sinophils, mast cells, and lymphocytes) was observed in the
lamina propria and submucosa of beclomethasone-treated pa-
tients compared to the placebo-treated group.
In a different study, the effect of the corticosteroid
budesonide was evaluated alone or in combination with the
β2-agonist formoterol [70]. The combined treatment of asth-
matic patients with formoterol and budesonide reduced spu-
tum eosinophilia significantly more than budesonide on its
own. Remarkably, while budesonide failed to attenuate the
increase in submucosal myofibroblast numbers following
antigen inhalation, the combined treatment reduced their num-
ber to near-baseline levels.
A reduction in the number of submucosal myofibroblasts,
lymphomononuclear cells, and macrophages was also ob-
served in antigen-challenged asthmatic patients after treatment
with the leukotriene receptor antagonist montelukast [71].
Interestingly, the number of lymphocytes increased after
montelukast treatment, and no effect was observed on eosin-
ophils and mast cells.
Respiratory System—Others
In addition to its use as a putative therapeutic agent for IPF (as
discussed earlier on), IFN-γ has been investigated as potential
treatment of other fibrotic pathologies; however, its efficacy
and safety remain unclear. In 2004, a placebo-controlled ran-
domized trial showed that aerosolized IFN-γ failed to both
improve FEV and reduce sputum bacterial density in patients
with cystic fibrosis lung disease and caused an exacerbation of
pulmonary symptoms at higher dosages [72]. However, com-
bined treatment with IFN-γ and prednisolone successfully
ameliorated respiratory symptoms in patients suffering from
bronchiolitis obliterans resulting from exposure to mustard
gas in the 1980–1988 Iran-Iraq war [73]. After six months of
treatment, the IFN-γ/prednisolone group showed significant
improvement in FEV1 and reduction in dyspnea and hospital-
ization compared to the prednisolone-only control group. In a
different study, fluticasone propionate was used to prevent
bronchiolitis obliterans syndrome (BOS) in clinically stable
lung transplant recipients [74]. Interestingly, BALF TGF-β1
levels increased considerably within the fluticasone-treated
group; however, the difference between case and control
group was not statistically significant. No significant
Table 2 (continued)
Ref Treatment Key outcomes Side effects Current
status*
[109] Topical tranilast in patients with lacrimal
gland GVHD
Improvements in Rose Bengal and Schirmer
test score
None observed MO
[110] Oral fluimucil in patients with acute
myocardial infarction
↓ Blood TGF-β1 levels Not discussed MO
[111] Preoperative palmar injection of
depo-medrone in patients with
Dupuytren’s disease
↑ Apoptosis of macrophages and fibroblasts
↓ fibroblast proliferation
Not discussed MO
[112] Intranodular adalimumab in patients with
Dupuytren’s disease
↓ α-SMA and procollagen I protein levels 2 SAE thought to be independent from treatment MO
[113] Oral tadalafil and/or intralesional verapamil
in patients with Peyronie’s disease
Improved clinical symptoms in combination
group
Hematoma at the injection site, dyspepsia,
headache, back pain, myalgia, flushing
MO
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difference in FEV scores and BOS occurrence was observed
between the two groups.
Skin
Wound Healing
The last decade has seen an upsurge of clinical research aimed
at minimizing scarring following skin wounds. The results of
three phase I/II randomized trials investigating the use of
avotermin (human recombinant TGF-β3) as a potential anti-
scarring therapeutical agent were described in a 2009 Lancet
paper [75]. Intradermal avotermin administration significantly
reduced scarring compared to placebo; post-healing histolog-
ical analysis showed that the ECM of avotermin-treated
wounds resembled that of normal skin more closely than
placebo-treated wounds. A successive study further confirmed
the anti-scarring effect of different regimes of intradermal
avotermin, indicating that treatment with 50 to 200 ng
avotermin/100 μl/linear cm significantly improves scar ap-
pearance at 6 and 12 months after wounding [76]. While the
trials described above were performed on healthy volunteers,
two further studies by the same research group confirmed the
scar-reducing effect of intradermal avotermin administration
in patients undergoing, respectively, scar revision surgery and
varicose vein removal surgery [77, 78].
The cytokine bFGF (FGF-2) has shown considerable pre-
clinical evidence of antifibrotic activity. Skin graft recipients
treated with topical bFGF showed a reduction in post-
operative scar colour change compared to placebo-treated
controls; histological analysis of skin biopsies showed an im-
provement in dermal arrangement, a wider cytoplasmic area,
and more organized collagen bundles [79]. Similar results
were obtained following topical bFGF administration in pae-
diatric second-degree burn victims [80]. A marked decrease in
the number of hypertrophic scarring events was observed after
1 year in the bFGF-treated patients, whose scars showed sig-
nificant improvements in terms of pigmentation, pliability,
height, and vascularity compared to placebo-treated controls.
Keloids
Two independent placebo-controlled trials conducted in the
1990s evaluated the effect of IFN-γ administration as an
anti-scarring treatment for keloids. In the former, intralesional
IFN-γ injection resulted in a statistically significant reduction
of keloid height (no changes were observed in lateral dimen-
sions) and visible histological changes, most notably the ab-
sence of neutrophils in the stratum corneum and a reduction in
collagen bundle thickness [81]. In the latter, IFN-γ was ad-
ministered three weeks after surgical excision of the keloids to
prevent their recurrence. At 12 weeks and 13 months post-
operation, no significant variation in keloid recurrence and
size could be observed between patients treated with IFN-γ
and placebo [82]. It is worth mentioning that both trials in-
volved a small number of subjects (8 and 7 respectively),
which could explain the contradictory findings on the effec-
tiveness of IFN-γ administration.
Localized Scleroderma and Systemic Sclerosis
Patients with localized scleroderma were administered subcu-
taneous IFN-γ or placebo intralesionally over a period of
6 weeks and tested for 18 weeks thereafter [83].
Interestingly, although the treatment did not affect lesion size
and collagen I production, patients treated with IFN-γ showed
a reduction in new lesions, indicating that IFN-γmight exert a
prophylactic rather than therapeutic function.
In a different phase II study, administration of topical
pirfenidone resulted in a reduction of the modified Localized
Scleroderma Skin Severity Index (mLoSSI) and skin hardness
in patients with localized scleroderma [84]. Histopathological
analysis of the lesions also highlighted a reduction in dermal
infiltration and reticular dermis fibrosis following pirfenidone
treatment.
The tyrosine kinase inhibitor nilotinib has been tested for
its ability to interfere with profibrotic signalling pathways in
systemic sclerosis (SSc). Patients that exhibited higher im-
provements in modified Rodnan skin score (MRSS) following
systemic administration of nilotinib showed a concomitant
overexpression of genes associated with TGFBR and
PDGFRB signalling, indicating a correlation between the in-
hibition of the TGF-β and PDGF pathways and amelioration
of skin fibrosis [85].
Immunomodulatory monoclonal antibodies have shown
promising potential for the treatment of systemic sclerosis.
Targeting CD20+ cells with rituximab (RTX) resulted in the
overexpression of the Wnt pathway inhibitor Dickkopf-1 in
systemic sclerosis patients [86]. Moreover, RTX-treated pa-
tients showed a marked reduction in dermal TGF-β (subtype
not specified) expression; histological analysis highlighted
enhanced resolution of skin fibrosis following treatment, indi-
cating that RTX-mediated B cell depletion might be an effi-
cient strategy for the treatment of fibrotic conditions with an
autoimmune aetiology. Fresolimumab (a monoclonal anti-
body targeting all TGF-β isoforms) was used to treat patients
with early diffuse SSc. Fresolimumab-mediated TGF-β
Inhibition resulted in a significant downregulation of
TGF-β-regulated biomarkers, a reduction in dermal
myofibroblast infiltration, and a drastic improvement of clin-
ical symptoms of fibrosis, supporting the observation of a
causative role of TGF-β signalling in SSc aetiology [87].
Immunomodulation via extracorporeal photochemotherapy
(ECP) was successfully used to attenuate fibrosis progression in
patients with diffuse cutaneous SSc [88]. Following ECP treat-
ment, patients showed a decrease in dermal thickness,
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improvements in modified Rodnan skin score, and a significant
reduction in circulating TGF-β levels.
Liver
Fibrosis in Patients with Chronic Viral Hepatitis
Out of the 10 trials identified in this study that focused on the
treatment of liver fibrosis, 7 involve patients who developed
the condition as a consequence of chronic viral hepatitis,
reflecting the key role of HBV and HCV infection in the
aetiology of liver fibrosis.
Due to their established activity as both antiviral and
antifibrotic agents, interferons have been widely investigated
as therapeutic agents for the treatment of viral hepatitis and
prevention of the associated liver fibrosis. In a randomized
controlled trial, HBV-positive patients were treated with intra-
muscular IFN-γ over a period of 9 months [89]. While no
significant difference in viral load was observed between the
two groups, patients in the treatment group showed a signifi-
cant reduction in hepatic fibrosis score and inflammatory
score compared to the control. Moreover, immunohistochem-
ical analysis indicated that IFN-γ treatment resulted in a
marked reduction in nuclear Smad2 and in the number of
hepatic stellate cells (HSC, a myofibroblasts-like α-SMA-
positive cell type); these findings are consistent with a repres-
sion of TGF-β signalling in HSC and hepatocytes.
Comparable observations (unchanged viral load, reduction
in fibrosis score, and α-SMA immunoreactivity) were report-
ed after treatment of HCV-positive patients with subcutaneous
IFN-γ [90]. Interestingly, the results of a different trial pub-
lished in the same year indicated that while treatment with
interferon alone (subtype not specified) could not decrease
serum fibrosis markers in patients with chronic HCV infec-
tion, it did significantly potentiate the antifibrotic effect of the
ACE inhibitor perindopril [91]. A multicentre randomized
placebo-controlled trial was carried out to evaluate the
antifibrotic effects of IFN- γ1b in 502 patients with chronic
HCV infection [92]. While IFN-γ1b was generally well toler-
ated, no significant differences in viral load and Ishak fibrosis
score were observed between the case and control groups. A
regime of subcutaneous pegylated IFN-α2a was supplement-
ed with AT1 antagonists (either telmisartan or losartan) in
HCV-positive patients [93]. No significant changes in rapid
(RVR) and early (EVR) virological response were observed
between the treatment groups; however, treatment with
telmisartan resulted in significant decreases in serum
TGF-β1 levels and urinary hydroxyproline and a concomitant
reduction in Ishak fibrosis score.
Salvia miltiorrhiza (red sage) is frequently used in tradition-
al Chinese medicine (TCM) for the treatment of liver fibrosis
and cirrhosis, and its derivative salvianolic acid B (SA-B) has
been shown to exhibit antifibrotic activity in preclinical studies.
The effectiveness and safety of SA-B for the treatment of liver
fibrosis in HBV-positive patients were evaluated in comparison
to IFN-γ and placebo [94]. While no reduction in HBV load
was observed, both SA-B and IFN-γ caused an amelioration of
inflammatory and fibrotic score compared to placebo, further
suggesting that the antifibrotic effect of the treatment may not
be directly caused by a reduction in viral titre. Similarly, while
no further reduction of HBV viral load was observed when
supplementing antiviral therapy with ginseng extract (also fre-
quently used in TCM as an antifibrotic agent), the combined
treatment resulted in a significant reduction in serological
markers of liver fibrosis (TGF-β and hyaluronic acid) [95].
Fibrosis in Patients with Non-alcoholicFibrosis in Patients
with Non-alcoholic
SteatohepatitisNon-alcoholic steatohepatitis (NASH) is an in-
creasingly prevalent pathology in developed countries, and is
often associated with liver fibrosis. The PIVENS trial was
carried out to assess the therapeutic effect of pioglitazone or
vitamin E (VitE) in NASH patients [96]. Although treatment
with pioglitazone resulted in a reduction in steatosis and lob-
ular inflammation, only VitE caused a significant rate of im-
provement in NASH patients. A successive study based on the
PIVENS trial reported that the amelioration of NASH symp-
toms following VitE treatment correlates with a reduction in
both Shh signalling and myofibroblast accumulation [97].
NASH patients with liver fibrosis stages 1–3 were enrolled
in a multicentre randomized phase IIa trial to evaluate the
safety and efficacy of pegbelfermin (PEGylated human
FGF21) [98]. Pegbelfermin treatment caused a significant re-
duction in hepatic fat fraction, liver stiffness, and serum PRO-
C3 (N-terminal type III collagen propeptide, an established
fibrosis marker) compared to placebo.
Kidney
Renal Allograft Fibrosis
Post-transplantation chronic allograft nephropathy is typically
characterized by tubulointerstitial fibrosis, glomerulosclerosis,
and vascular sclerosis ultimately resulting in allograft failure.
A substantial body of research has gone into investigating
immunosuppression strategies to prevent both allograft rejec-
tion and fibrotic degeneration. The calcineurin inhibitors
(CNI) cyclosporine and tacrolimus are routinely administered
to kidney transplant patients as immunosuppressive agents;
however, CNI use has been linked to the insurgence and pro-
gression of kidney fibrosis. A randomized clinical trial de-
signed to test the differential effect of the two drugs on the
expression of fibrosis-associated genes indicated that cyclo-
sporin treatment resulted in a higher expression of collagen III
and TIMP-1 compared to tacrolimus after a week post-
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transplant [99]. While these findings might suggest that tacro-
limus could be a more efficient immunosuppressive agent to
prevent the development of fibrosis in allograft recipients, it is
worth mentioning that no significant difference in the expres-
sion of the analysed profibrotic markers could be observed at
3 and 6 months post-transplant. In addition to tacrolimus,
other macrolide immunosuppressors (sirolimus and everoli-
mus) have been tested in kidney transplant recipients for po-
tential profibrotic activity. The effects of early withdrawal
from a CNI regime were tested in a randomized trial, whereby
patients on a combined regime of tacrolimus, sirolimus, and
prednisone were randomized in two groups; one group (SRL)
received no tacrolimus and an increased dose of sirolimus, and
the other group (TAC) was maintained on a tacrolimus regime
[100]. Maintenance of tacrolimus resulted in an increase in
collagen and α-SMA, as well as in TGF-β, its receptors
TGF-β-R1 and R2, and p-Smad2/3, indicating the presence
of a sustained profibrotic signal mediated by the TGF-β/Smad
pathway and resulting in myofibroblast activation, consistent-
ly with previous reports of CNI-induced kidney fibrosis.
Similar results were obtained in another trial comparing the
effects of CNI-containing and CNI-free immunosuppressive
regimens: allograft recipients were treated with mycopheno-
late mofetil (MMF), prednisone, daclizumab (CNI-free group)
or MFF, prednisone, and cyclosporine (CNI group) [101].
After 1 year from transplantation, the CNI group exhibited a
significantly higher serum TGF-β1 concentration and intersti-
tial fibrosis/tubular atrophy. However, a different study report-
ed that cyclosporine withdrawal failed to reduce fibrosis pro-
gression [102]. Patients on a cyclosporine regime were ran-
domized to either maintain cyclosporine administration or
switch to a non-CNI regime (everolimus). No significant re-
duction in interstitial fibrosis/tubular atrophy was observed in
the non-CNI group. Moreover, cyclosporine withdrawal re-
sulted in a marked increase in biopsy-proven acute rejection,
indicating that a CNI regime might be necessary to maintain
adequate immunosuppression in kidney transplant recipients.
Interestingly, a clinical trial evaluating different treatment
strategies to control post-transplant hypertension revealed that
losartan (an angiotensin II receptor blocker) significantly de-
creased the plasma levels of TGF-β1 [103].
Non-diabetic Kidney Disease
In addition to angiotensin receptor blockers, other classes of
compounds including angiotensin-converting enzyme inhibi-
tors (ACEIs) and angiotensin receptor blockers (ARBs) have
been investigated to target components of the renin-
angiotensin-aldosterone system (RAAS) in an attempt to re-
duce kidney fibrosis. Addition of spironolactone (an aldoste-
rone receptor blocker) to a regimen of ARB/ACEI resulted in
a decrease in urinary TGF-β1 levels in patients with non-
diabetic chronic kidney disease [104]. Similarly, a significant
reduction in urinary TGF-β1 levels was observed in patients
with non-diabetic chronic kidney disease after treatment with
the ACEI perindopril or the renin inhibitor aliskiren compared
to placebo; no significant differences were observed between
aliskiren and perindopril treatment [105].
In a randomized controlled trial, patients with adult diffuse
proliferative IgA nephropathy were administered either the
corticosteroid prednisolone or the antiplatelet dipyridamole
[106]. Histological analysis of glomerular biopsies indicated
that prednisolone treatment significantly reduced α-SMA ex-
pression, mesangial cell proliferation, and matrix accumula-
tion, whereas no significant changes were observed in inter-
stitial cellular infiltrates and tubulointerstitial fibrosis.
Other Organs and Syndromes
Eye
The scar-preventing activity of anti-TGF-β2 monoclonal anti-
body CAT-152 (lerdelimumab) was tested via a multicentre ran-
domized phase III trial in glaucoma patients undergoing first-
time trabeculectomy [107]. Subconjunctival injections of CAT-
152 before and after surgery were well-tolerated and did not
cause any adverse effects; however, treatment did not reduce
intraocular pressure, bleb vascularity, and overall
trabeculectomy failure rate compared to placebo. Likewise, pre-
surgery bevacizumab-mediated VEGF targeting failed to reduce
collagen deposition and α-SMA expression in fibrovascular
epiretinal membranes excised via vitrectomy from proliferative
diabetic retinopathy patients [108]. Tranilast (n-[3,4-anthoranilic
acid]) is an anti-allergic drug known to inhibit TGF-β signalling
and ECM deposition in vitro and in vivo. Topical tranilast ad-
ministration successfully reduced the progression of mild dry
eye in patients with chronic graft versus host disease; the authors
suggest that tranilast treatment might achieve this result by re-
ducing fibrotic degeneration of the lacrimal gland and ducts
typically associated with the condition [109].
Heart
Fibrotic remodelling of the myocardium has been associated
with increased morbidity and mortality in patients affected by
acute myocardial infarction (AMI). A double-blind, placebo-
controlled randomized trial was carried out to test the effect of
the antioxidant N-acetylcysteine (NAC) on TGF-β and
TNF-α serum levels at 24 and 72 h post-infarction [110].
While TNF-α levels did not show any variation within and
between groups, TGF-β levels increased significantly over
time within the placebo group, but not in the NAC group. In
the same study, higher TGF-β levels were reported to corre-
late with increased MMP-9 levels and reduced left ventricle
ejection fraction.
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Dupuytren’s Disease
Palmar fascia biopsies were obtained from Dupuytren’s dis-
ease patients preoperatively injected with methylprednisolone
acetate and untreated patients to assess the antifibrotic poten-
tial of steroids [111]. Immunohistochemical assessment indi-
cated that steroid treatment resulted in reduced proliferation
(Ki67) of fibroblasts and increased apoptosis (Lewis Y) of
macrophages and fibroblasts. Interestingly, flow cytometry
indicated that Dupuytren’s cells had a tenfold increase in ap-
optosis rate following steroid treatment in vitro, a response
that was not observed in control fascial tissue. These findings
suggest that steroid treatment might be a promising strategy to
promote apoptosis and reduce proliferation of fascial
(myo)fibroblasts in Dupuytren’s disease. A different approach
to the pharmacological treatment of Dupuytren’s disease in-
volves targeting TNF with the monoclonal antibody
adalimumab. In a phase II placebo-controlled dose-response
study, patients with Dupuytren’s disease were randomized to
receive different dosages of adalimumab or equivalent vol-
umes of saline [112]. After two weeks from intranodular in-
jection, patients who received the highest dose (40 mg) of
adalimumab showed significant reductions in α-SMA and
procollagen I protein levels, compatible with an inhibition of
the myofibroblast phenotype. Interestingly, no changes in
mRNA expression were observed for any of the analysed
markers between the different treatment groups, indicating
that α-SMA and procollagen I levels might be predominantly
regulated at a post-transcriptional level.
Peyronie’s Disease
Peyronie’s disease (PD) is characterized by the formation of
scar tissue plaques in the penile tunica albuginea.
Phosphodiesterase 5 (PDE5) inhibitors (most frequently
tadalafil) have been successfully used to treat PD in a preclin-
ical and clinical context. In a prospective, randomized trial PD
patients were administered oral tadalafil, intralesional verapa-
mil (a calcium channel blocker) injections, or a combination
of the two over a period of 2 months [113]. The combined
treatment resulted in a significant reduction of plaque size and
amelioration of clinical symptoms compared to the individual
treatment regimes, suggesting that intralesional calcium chan-
nel blockers might potentiate the effect of systemic PDE5
inhibitors.
Discussion and Conclusions
The clinical data collected in this review indicate not only that
therapeutic strategies vary greatly between different fibrotic
conditions but also that the same strategy might have widely
variable efficiency and outcome depending on the nature of
the targeted organ. A cogent example is provided by therapies
based on IFN-γ administration: strikingly, for many of the
pathologies in exam (pulmonary fibrosis, bronchiolitis
obliterans, keloids, scleroderma, viral hepatitis), different tri-
als show IFN-γ to have positive effects, no significant effect,
or even detrimental effects on the progression and symptoms
of fibrosis. While the efficacy and safety of IFN-γwas trialled
across a range of pathologic conditions, most therapeutical
strategies identified in this study appear to be less “promiscu-
ous” and reflect the different upstream aetiological factors
underpinning each condition. It is worth emphasizing that, in
the majority of the successful trials evaluated in this review, a
direct correlation could be observed between a reduction in
myofibroblast differentiation markers (most notably TGF-β1
levels, α-SMA expression, ECM deposition and remodelling)
and improvements in organ functionality and clinical indica-
tors of fibrosis. The next paragraphs summarize the pharma-
cological approaches that have ameliorated fibrosis symptoms
and/or improved organ functionality in patients and attempt to
unearth any commonalities between successful therapeutical
strategies.
Serum amyloid P and nintedanib successfully improved
pulmonary function in IPF patients, providing evidence that
inhibition of fibrocyte proliferation and activity might be a
viable therapeutic strategy [114]. Given the role of inflamma-
tory processes in the pathogenesis of asthma, it is not surpris-
ing that steroid treatment could be successfully used to sup-
plement standard bronchodilator regimes to ameliorate airway
remodelling and fibrosis associated with this condition [115,
116].
Both TGF-β3 and bFGF showed good tolerability and sig-
nificantly reduced scarring in surgical wounds in all the trials
analysed in this review, suggesting that topical administration
of antifibrotic cytokines is a promising approach to limiting
hypertrophic scarring associated with surgical procedures.
Paradoxically, while the in vivo antifibrotic activity of
TGF-β3 has been demonstrated in both preclinical and clini-
cal settings, the cytokine has been shown to induce α-SMA
expression in vitro and collagen deposition in vivo, indicating
that further research might be necessary to prevent unwanted
side effects [48]. It is worth emphasizing that while the phase
I/II trials discussed in this review indicate that TGF-β3 could
successfully minimize surgical wound scarring, it failed to
achieve the phase III trial endpoints in a successive trial, the
results of which were not subsequently published in a peer-
reviewed academic journal [117].
Improvements of clinical symptoms in patients with local-
ized or systemic sclerosis were obtained via pharmacological
inhibition of Wnt (pirfenidone, rituximab) and TGF-β/Smad
(fresolimumab, nilotinib) signalling, confirming preclinical
observations of the synergistic effect of the two pathways in
the pathogenesis of skin fibrotic disorders [118, 119].
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Due to their established activity as both antiviral and
antifibrotic agents, interferons have been widely investigated
as therapeutic agents for the treatment of viral hepatitis and
prevention of the associated liver fibrosis. Interestingly, three
different clinical trials highlighted that while IFN-γ was un-
able to reduce HBVand HCV load, it was successful in reduc-
ing myofibroblast presence and fibrosis score in patients with
chronic viral hepatitis. Conversely, data from other clinical
trials seems to indicate that while treatment with IFN- γ may
not be sufficient to ameliorate liver fibrosis symptoms on its
own, it does seem to potentiate the effect of ACE inhibitors
and AT1 antagonists. A substantial body of literature exists
regarding the use of CHM remedies to treat chronic viral hep-
atitis [120]. The current review identified two such clinical
trials in which, respectively, salvianolic acid-B and ginseng
extract were successful in reducing fibrosis markers in patients
with chronic HBV infection. In two further clinical trials, he-
patic fibrosis symptoms were improved by treating NASH
patients with, respectively, vitamin E and pegbelfermin.
Five of the identified trials investigated strategies to ame-
liorate or eliminate CNI-induced fibrosis in kidney allograft
recipients. In all but one of the studies, withdrawal from a
CNI-based immunosuppressive regime resulted in a reduction
in kidney fibrosis markers; these results corroborate the
burgeoning body of evidence pointing to the necessity of de-
vising alternative immunosuppressive strategies to the rou-
tinely used tacrolimus and cyclosporine regimes [121].
Pharmacological targeting of different RAAS components re-
sulted in a reduction of TGF-β 1 levels in patients with non-
diabetic kidney disease, whereas prednisone reduced α-SMA
expression but failed to ameliorate tubulointerstitial fibrosis in
patients with diffuse proliferative IgA nephropathy.
Inhibition of TGF-β signalling is a promising strategy to
prevent scarring following eye surgery. Interestingly, while
anti-TGF-β2 monoclonal antibodies failed to reduce intraoc-
ular pressure and ultimately trabeculectomy failure ratio,
broad-spectrum TGF-β inhibition via tranilast successfully
reduced the progression of mild dry eye in chronic GVHD
patients. These observations indicate that given the profibrotic
nature of both TGF-β1 and β2 and their action through a
shared set of receptors, strategies aimed at blocking TGF-β
receptors (as is the case for tranilast) might be more effective
than targeting the growth factors themselves [122, 123].
Surgical approaches such as open fasciectomy and percu-
taneous needle aponeurotomy are currently the gold standard
for the treatment of Dupuytren’s disease [124]. However, the
clinical data evaluated in the present review highlight that
anti-inflammatory strategies such as steroid treatment and
TNF-α signalling inhibition might successfully reduce
myofibroblast persistence and activity, making it a promising
approach to complement (or potentially replace) the need for
surgical procedures. Similarly, while surgery is still consid-
ered the gold standard for the treatment of Peyronie’s disease,
an increasing body of research investigates non-surgical alter-
natives to its management [125]. Clinical data analysed in this
review indicate that the combined use of tadalafil and verap-
amil significantly ameliorated clinical symptoms in PD pa-
tients. As verapamil had previously been show to also poten-
tiate collagenase activity in PD plaques, further clinical inves-
tigation would be beneficial to investigate whether the com-
bined administration of PDE5 inhibitors, calcium channel
blockers, and collagenase might be a viable strategy for the
non-surgical treatment of PD [126, 127].
Despite abundant preclinical evidence supporting the
antifibrotic activity of interleukin-1, none of the trials identi-
fied in this review evaluated its effect in a clinical context. A
simple explanation of this observation could be the well-
documented proinflammatory effect of this cytokine, which
might result in the onset of unwanted side effects; unsurpris-
ingly, a wealth of clinical research is focused on the inhibition,
rather than promotion, of IL-1 activity [128]. While systemic
administration of IL-1 should not be considered a viable treat-
ment strategy, further research is required to assess whether its
potential antifibrotic activity might outweigh the risk of side
effects when administered topically.
This review consolidates the notion that, despite the simi-
larities in cellular and molecular mechanisms underlying fi-
brotic degeneration in different organs, there is currently no
“one size fits all” approach towards its pharmacological treat-
ment. Moreover, said mechanisms often show a pleiotropic
regulatory action during the onset and progression of fibrosis.
This, together with the presence of positive feedback loops,
makes it difficult (if at all possible) to precisely pinpoint which
phase of the process is being targeted by each treatment.
However, the present study indicates that the systematic eval-
uation of clinical data can unearth trends and connections
between approaches used to successfully treat different fibrot-
ic pathologies, informing and facilitating the future design of
therapeutical strategies specific for each condition. Due to
space constraints, the search strategy utilized in this review
was limited to (and by) the use of only four cytokines as
proxies of myofibroblast activity, as they had previously been
identified as the most well-established myofibroblast-
repressing factors. Future studies might be required to expand
on the present investigation by focusing on other molecules
that have shown anti-fibrotic potential in a preclinical setting.
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